hpparδ

NXT629 is a selective and highly efficient PPAR-α antagonist with anticancer activity. It inhibits PPARδ, PPARγ, Erβ, GR, and TRβ and can be used in research on ovarian cancer and melanoma.

Muraglitazar (BMS-298585) is a PPAR α/γ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα and PPARγ with EC50 of 320 nM and 110 nM respectively.

sEH/PPARδ modulator 1 is a dual regulator of sEH and PPARδ. It inhibits sEH with an IC50 of 0.46 μM and activates PPARδ with an EC50 of 0.12 μM. This compound is applicable in research related to inflammation, metabolic disorders, and cardiovascular diseases.

PPARδ agonist10 (compound 7) is an orally active, selective partial agonist of PPARδ, with EC50 values of 0.053 μM for hPPARδ(LBD)-GAL4 and 0.30 µM for mPPARδ. In transactivation assays, it acts as a partial PPARδ agonist but fully stimulates muscle cell free fatty acid oxidation both in vitro and in vivo. PPARδ agonist10 can be utilized for dyslipidemia research.